Guardant Health, Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Broad Growth: The quarter featured broad-based growth across oncology, biopharma, and screening. Oncology volumes saw a 40% year-over-year increase, biopharma had positive CDx momentum, and screening revenue accelerated.
• Patient Impact: Highlighted a patient story where a 67-year-old benefited from a Shield blood test, leading to early detection of colorectal cancer and successful treatment.
• Product Milestones: Submitted a PMA application for Guardant360 Liquid to the FDA, had a strong presence at ESMO 2025 with 15 abstracts, and made progress in Reveal's data pipeline for MRD and other indications.
• Strategic Partnerships: Announced collaborations with Quest Diagnostics and PathGroup to scale Shield's commercial infrastructure, expanding access to the test.

Segment Performance

• Oncology: Revenue increased 31% to $184 million in Q3 2025, with oncology volumes growing 40% year-over-year to approximately 74,000 tests. This segment contributed significantly to overall revenue growth.
• Biopharma and Data: Generated revenue of $54.7 million, up 18% year-over-year, driven by positive momentum in companion diagnostic approvals.
• Screening: Shield testing revenue totaled $24.1 million from 24,000 tests in Q3. Screening has an annual run rate of approximately $100 million, with Shield tests showing strong adoption and generating meaningful revenue.

Guidance

• Revenue: Raised full-year 2025 revenue guidance to $965 million to $970 million, representing 31% year-over-year growth. Oncology revenue is expected to grow ~25%, and biopharma mid-teens growth is anticipated.
• Shield: Increased Shield revenue guidance to $71 million to $73 million, driven by higher test volumes. Non-GAAP gross margin guidance raised to 64% to 65%.
• Cash Flow: Core business expected to be free cash flow positive in Q4 2025 and beyond, with continued focus on reducing cash burn.

Risks

• Regulatory Uncertainties: Uncertainties related to FDA approvals for products like Guardant360 Liquid and reimbursement policies.
• Competition: Potential competition in the liquid biopsy and cancer screening markets could impact market share.
• Reimbursement Dependence: Reliance on Medicare and commercial payer reimbursements for sustained growth, which may face challenges.

Question and Answer

• Q: Bradley Bowers asked about Shield ASP dynamics. A: Mike Bell discussed Medicare rates, Medicare Advantage payments, and future commercial reimbursement expectations.
• Q: Doug Schenkel inquired about ACS guideline inclusion and reimbursement. A: AmirAli Talasaz talked about ACS progress and potential impact on Shield's commercial coverage.
• Q: Puneet Souda asked about Shield growth and Guardant360. A: AmirAli and Helmy Eltoukhy discussed Shield's momentum and Guardant360 as a platform with expanding clinical utility.
• Q: Subbu Nambi asked about MCD FDA timeline. A: AmirAli stated the timeline for MCD FDA approval is not specific yet and will be monitored closely.
• Q: Patrick Donnelly asked about Reveal traction. A: Helmy Eltoukhy discussed Reveal's progress in reimbursement and increasing test per patient through longitudinal testing.
• Q: Tycho Peterson asked about PEGASUS data and NCCN guidelines. A: Helmy Eltoukhy talked about PEGASUS study findings and clinical utility of Reveal in adjuvant and surveillance settings.
• Q: William Bonello asked about G360 growth drivers. A: Helmy Eltoukhy discussed market penetration, concurrent testing of tissue and liquid, and potential for multiple tests per patient.
• Q: Mark Massaro asked about Shield sequential growth and Reveal Ultra. A: AmirAli and Helmy Eltoukhy discussed Shield's sequential growth and progress on Reveal Ultra's tumor-informed technology.
• Q: Casey Woodring asked about Shield KPIs and gross margin. A: AmirAli and Michael Bell discussed Shield's high adherence rates and progress in gross margin improvement for both Shield and Reveal.
• Q: Kyle Mikson asked about Reveal ADLT status and Shield competition. A: Helmy Eltoukhy discussed ADLT status timeline and AmirAli addressed Shield's competitive position in the market.
• Q: Luke Sergott asked about OpEx spend. A: Michael Bell discussed OpEx investment in sales and marketing to scale Shield and oncology commercial infrastructure.
• Q: Daniel Brennan asked about G360 volume guide and acceleration. A: Michael Bell and Helmy Eltoukhy discussed Q4 volume guide expectations and growth drivers like share gains and concurrent testing.
• Q: Daniel Arias asked about Reveal reimbursement. A: Michael Bell talked about Reveal's CRC reimbursement progress and future expectations for Medicare and commercial payer reimbursements.